ADAM15 and glioblastoma: Strikingly, ADMA10 and ADAM15 AngioMatrix proteins were the only ones that presented predictable missense pathogenic mutations, highlighting the AngioMatrix signature as a valuable source of biomarkers for GBM progression follow up.